Clinical Trial

A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2023 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II, single-arm study to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-27.
Status change: Not Yet Recruiting → Recruiting 2023-07-14
Trial Details
NCT Number NCT05837052
Lead Sponsor Zhejiang University
Conditions Unresectable Lung Non-Small Cell Carcinoma
Enrollment 49 participants
Start Date 2023-05-15
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2023-07-17